Filing Flows › Amphastar Pharmaceuticals (AMPH) › Q3 2026 › vs Q3 2025
Amphastar Pharmaceuticals (AMPH) Q3 2026 vs Q3 2025 (year over year)
Amphastar Pharmaceuticals's revenue rose $15.8M (+8%) from $192M in Q3 2025 to $208M in Q3 2026. Gross margin 48.0% against 51.4% (-3.4 pts).
Amphastar Pharmaceuticals, Q3 2026: revenue $208M (+8% year over year), operating margin 24.5%, net earnings $37.8M, operating cash flow $43.3M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 48.0% | 51.4% | -3.4 pts |
| Operating margin | 24.5% | 13.2% | +11.3 pts |
| Net margin | 18.2% | 9.0% | +9.1 pts |
| Free cash flow margin | 16.1% | 24.6% | -8.6 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $208M | $192M | $15.8M | +8% |
| Gross profit | $99.6M | $98.6M | $983K | +1% |
| Cost of revenue | $108M | $93.2M | $14.8M | +16% |
| Operating profit | $50.8M | $25.3M | $25.5M | +101% |
| Operating expenses | $48.9M | $73.3M | −$24.5M | -33% |
| Pre-tax earnings | $49.1M | $21.5M | $27.6M | +128% |
| Other expense, net | $1.7M | $3.8M | −$2.1M | -55% |
| Research & development | $20.1M | $22.4M | −$2.3M | -10% |
| Sales & marketing | $11.9M | $11.5M | $429K | +4% |
| General & admin | $16.8M | $39.5M | −$22.6M | -57% |
| Net earnings | $37.8M | $17.4M | $20.4M | +118% |
| Income tax | $11.3M | $4.2M | $7.1M | +171% |
| Depreciation & amortization | $15.6M | $14.1M | $1.5M | +10% |
| Share-based compensation | $7.0M | $6.3M | $710K | +11% |
| Working capital & other | $17.1M | −$14.8M | $31.9M | — |
| Operating cash flow | $43.3M | $52.6M | −$9.3M | -18% |
| Free cash flow (OCF − capex) | $33.4M | $47.2M | −$13.9M | -29% |
| Capital expenditures | $9.9M | $5.3M | $4.6M | +86% |
Questions
How much did Amphastar Pharmaceuticals's revenue grow year over year in Q3 2026?
Amphastar Pharmaceuticals's revenue rose $15.8M (+8%) from $192M in Q3 2025 to $208M in Q3 2026. Gross margin 48.0% against 51.4% (-3.4 pts).